Contemporary, industrial healthcare systems have understandably been designed to be sharply focused on the treatment of human illness, with the domination of incentives focused on activity (e.g. fee-for-service medicine; activity-based funding) have been suggested as a major contributor to this orientation. While this has encouraged a form of innovation that has driven the unprecedented expansion of population lifespan, more recent decades have failed to deliver a concomitant dividend in healthspan. In Australia, the AIHW 2023 Burden of Disease Report